British-based GW Pharmaceuticals announced positive Phase 3 study results and reported it's year-end earnings results. The company also said that Brexit and the election of Donald Trump in the U.S. could affect its business. GW only has one commercialized product at this time and that is Sativex, which is being used to treat spasticity due to multiple sclerosis. It is used in 30 countries outside of the U.S.GW also announced new Epidiolex positive phase 3 data in Dravet Syndrome and Lennox-Gastaut syndrome. They found a significant difference between Epidiolex and the placebo in seizure frequency reduction during the 14-week period.

Source: Forbes December 05, 2016 15:01 UTC